Clinical trial for Recurrent Glioblastoma, IDH-Wildtype
Official title Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
ClinicalTrials.gov ID: NCT05432804
What this study is testing
What is Selinexor?
Selinexor is an investigational medicine, taken by mouth once daily, being studied as a potential treatment for recurrent glioblastoma, idh-wildtype.
Also referred to as ATG-010, CRM1 Nuclear Export Inhibitor KPT-330.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study checks if adding selinexor to standard chemotherapy is safe and finds the best dose. It also compares this combination against standard chemotherapy alone to see if it works better.
- Who it's for
- People with a type of brain tumor called glioblastoma that has returned after previous treatment.
- What's involved
- Participants will receive selinexor along with standard chemotherapy (temozolomide) or just the standard chemotherapy. They will have regular checkups and tests to monitor their health and the tumor.
- Time commitment
- The study involves regular visits for treatment and monitoring over a period of time, though the exact duration is not specified in the provided text.
- Phase 2: a mid-size study of how well it works
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Patients must have histologically confirmed glioblastoma (IDH wild-type, MGMT promoter methylated) that has undergone resection or biopsy upon first...
- Prior to resection or biopsy, patients must have measurable disease, defined as at least one bi-dimensional contrast-enhancing lesion with clearly...
- Patients must have received first-line treatment of temozolomide plus radiotherapy
- Patients must not have received any prior therapy aside from resection or biopsy for their recurrent disease
- Age \>= 18 years. Because no dosing or adverse event data are currently available on the use of selinexor (KPT-330) in combination with temozolomide...
You likely can't join if
- Patients who have had chemotherapy must have full recovery of organ and marrow function following the nadir of the last chemotherapy cycle
- Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities \> grade 1) with the exception...
- Patients who are receiving any other investigational agents
- Patients who have previously received bevacizumab
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to selinexor (KPT-330) or temozolomide
- History of hypersensitivity to dacarbazine (DTIC), since both dacarbazine and temozolomide are metabolized to...
See the full eligibility criteria
- Patients must have histologically confirmed glioblastoma (IDH wild-type, MGMT promoter methylated) that has undergone resection or biopsy upon first recurrence.
- Prior to resection or biopsy, patients must have measurable disease, defined as at least one bi-dimensional contrast-enhancing lesion with clearly defined margins, with 2 perpendicular diameters of at least 10 mm...
- Patients must have received first-line treatment of temozolomide plus radiotherapy
- Patients must not have received any prior therapy aside from resection or biopsy for their recurrent disease
- Age \>= 18 years. Because no dosing or adverse event data are currently available on the use of selinexor (KPT-330) in combination with temozolomide in patients \< 18 years of age, children are excluded from this study
- Karnofsky performance status \>= 60% (Eastern Cooperative Oncology Group [ECOG] =\< 2)
- Absolute neutrophil count \>= 1,500/mcL
- Platelets \>= 100,000/mcL
- Hemoglobin \>= 10 g/dL
- Total bilirubin =\< 2 x institutional upper limit of normal (ULN)
- Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine transaminase (ALT) (serum glutamic-pyruvic transaminase [SGPT]) =\< 3 x institutional ULN
- Glomerular filtration rate (GFR) \>= 30 mL/min/1.73 m\^2
- Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
- For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
- Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
- Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or how well it works assessment of the investigational regimen are eligible for...
- Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association...
- The effects of selinexor (KPT-330) and temozolomide on the developing human fetus are unknown. For this reason and because selective nuclear export inhibitors as well as deoxyribonucleic acid (DNA) alkylating agents are...
- Ability to understand and the willingness to sign a written informed consent document. Participants with impaired decision-making capacity who have a legally-authorized representative (LAR) and/or family member...
- Patients who have had chemotherapy must have full recovery of organ and marrow function following the nadir of the last chemotherapy cycle
- Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities \> grade 1) with the exception of alopecia
- Patients who are receiving any other investigational agents
- Patients who have previously received bevacizumab
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to selinexor (KPT-330) or temozolomide
- History of hypersensitivity to dacarbazine (DTIC), since both dacarbazine and temozolomide are metabolized to 5-(3-methyltriazen-1-yl)-imidazole-4-carboxamide (MTIC)
- Patients with uncontrolled intercurrent illness
- Pregnant women are excluded from this study because selinexor (KPT-330) is a selective inhibitor of nuclear export with the potential for teratogenic or abortifacient effects.
- Hospitalized patients with severe coronavirus disease of 2019 (COVID-19) who are \>= 75 years old, or with a high-risk COVID-GRAM score, or with lactate dehydrogenase (LDH) \> 370 (U/L) AND D-Dimer \> 600 mcg/L FEU...
The study team makes the final eligibility decision.
Where it is enrolling
- Phoenix, Arizona, United States
- Duarte, California, United States
- Irvine, California, United States
- La Jolla, California, United States
- Los Angeles, California, United States
- Orange, California, United States
- Sacramento, California, United States
- Aurora, Colorado, United States
- Coral Gables, Florida, United States
- Deerfield Beach, Florida, United States
- Jacksonville, Florida, United States
- Miami, Florida, United States
- Tampa, Florida, United States
- Atlanta, Georgia, United States
- Chicago, Illinois, United States
- Orland Park, Illinois, United States
- Lexington, Kentucky, United States
- Rochester, Minnesota, United States
- Livingston, New Jersey, United States
- New Brunswick, New Jersey, United States
+ 10 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Phoenix, Arizona, United States; Duarte, California, United States; Irvine, California, United States; La Jolla, California, United States; Los Angeles, California, United States; Orange, California, United States and 24 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.